Gracell Biotechnologies is scheduled to make its debut on the Nasdaq Global Select Market today (January 8), under the ticker symbol "GRCL."
The Suzhou, China-based Gracell Biotechnologies is a global clinical-stage biopharmaceutical company developing CAR-T cell therapies for cancer through its proprietary technology platforms—FasTCAR and TruUCAR.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com